BioCentury
ARTICLE | Company News

Priority Review for Prometic’s plasminogen therapy

October 13, 2017 8:54 PM UTC

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said FDA accepted and granted Priority Review to a BLA for Ryplazim human plasma-derived plasminogen to treat plasminogen deficiency. Its PDUFA date is April 14, 2018.

The human plasma-derived plasminogen has Orphan Drug, Fast Track and rare pediatric disease designations from FDA...

BCIQ Company Profiles

Liminal BioSciences Inc.